Novozymes is a biotechnology firm engaged in the production and sale of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company operates through five segments organized by the sectors that it serves: Household Care, Food & Beverages, Bioenergy, Agriculture & Feed, and Tech & Pharma. Headquartered outside of Copenhagen, Denmark, the company has approximately 6,500 employees.
Novozyme’s biosolutions enable cost savings and reduced environmental impacts by decreasing the amount of raw materials used, replacing chemicals and improving product quality. For the agricultural, textile and chemical industries, the company’s offerings create the potential for significant energy savings, too. In a recent year, Novozyme’s customers avoided an estimated 60 million tons of CO2 emissions by using the company’s products. Additionally, the company documents the environmental benefits of each of its solutions through lifecycle analyses that enable customers to track reduced consumption, reach environmental goals and provide clear reporting on sustainability progress. By 2020, Novozymes aims to help its customers avoid 100 million tons of CO2 emissions annually while ensuring that 100% of its agricultural raw materials come from suppliers that do not contribute to deforestation. By the same year, the company hopes to decrease its footprint from operations by improving its energy efficiency 30%, water efficiency 25%, reducing its CO2 emissions intensity 25% and sourcing 30% of its total energy from renewable sources.
Novozymes has been fined for discharging hazardous waste into a river that killed almost 6,700 fish and caused three children to suffer from skin rashes and eye irritation. Additionally, the company has two women on its nine-person Board of Directors.
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 12/31/16 and may not reflect current opinions or subsequent events.